Trial Profile
A Randomized, Partially Blinded, 4-period, Crossover Study to Assess the Effects of Single-dose AEB071 Administration (300 and 900 mg) on Electrocardiographic QT Intervals Compared to Placebo in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2012
Price :
$35
*
At a glance
- Drugs Sotrastaurin (Primary) ; Moxifloxacin
- Indications B-cell lymphoma; Bacterial infections; Liver transplant rejection; Psoriasis; Renal transplant rejection; Ulcerative colitis; Uveal melanoma; Uveitis
- Focus Adverse reactions; Pharmacodynamics
- 15 May 2012 New trial record